Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer.
Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer.
复制标题
DOI：
10.1111/j.1349-7006.2000.tb00961.x
复制
发表时间：
2000-04
期刊：
影响因子：
--
通讯作者：
Yoshida K
中科院分区：
文献类型：
--
作者：
Koga F;Kitahara S;Arai K;Honda M;Sumi S;Yoshida K
评估了局部晚期膀胱移行细胞癌（TCC）患者对DNA损伤药物的临床反应与p53和p21状态之间的关系。在23例患者中评估了对动脉内化疗（IAC）（包括100 mg/m2顺铂（CDDP）和40 mg/m2吡拉西坦（THP））的反应和预后（平均随访期为19个月）。在19例患者中使用聚合酶链反应-单链构象多态性分析在外显子5-8处分析肿瘤的p53基因状态，并在23例患者中对石蜡包埋的肿瘤切片进行p53和p21免疫染色。总体客观缓解率（良好缓解者的发生率）为70%。p53阴性组（n=17）的客观缓解率显著高于p53阳性组（n=6）（82% vs. 33%; P=0.045）。p53基因状态或p21染色状态与反应性无显著相关。当p53和p21免疫染色结果相结合时，良好的反应比单独的p53染色状态更准确地预测; p53阴性/p21阳性组（n=12）显示客观反应率为92%，显著高于p53阳性和/或p21阴性组（45%，n=11）（P=0.027）。p53阴性组的病因特异性生存率显著上级p53阳性组（P=0.015）。p53阴性/p21阳性是膀胱移行细胞癌患者化疗反应良好的可能预测因子。
The relationship between clinical response to DNA‐damaging drugs and p53 and p21 status in patients with locally advanced transitional cell carcinoma (TCC) of the bladder was assessed. The response to intraarterial chemotherapy (IAC) comprising 100 mg/m2 of cisplatin (CDDP) and 40 mg/m2 of pirarubicin (THP) and the prognosis were assessed in 23 patients (the mean follow‐up period was 19 months). The p53 gene status of tumors was analyzed at exons 5–8 using polymerase chain reaction‐single strand conformation polymorphism analysis in 19 patients, and paraffinembedded tumor sections were immunostained for p53 and p21 in 23 patients. The overall objective response rate (incidence of good responders) was 70%. The negative p53 group (n=17) showed a significantly higher objective response rate than the positive p53 group (n=6) (82% vs. 33%; P=0.045). The p53 gene status or p21 staining status was not significantly associated with responsiveness. When the p53 and p21 immunostaining results were combined, good responders were more accurately predicted than by p53 staining status alone; the negative p53/positive p21 group (n=12) showed an objective response rate of 92%, which was significantly higher than that of the positive p53 and/or negative p21 group (45%, n=11) (P=0.027). Cause‐specific survival of the negative p53 group was significantly superior to that of the positive p53 group (P=0.015). Negative p53/positive p21 immunostaining is a possible predictor of favorable chemotherapeutic response in patients with TCC of the bladder.
登录
查看更多内容
影响因子：
64.8
作者：
Waldman, T;Lengauer, C;Vogelstein, B
通讯作者：
Vogelstein, B
影响因子：
64.5
作者：
ELDEIRY, WS;TOKINO, T;VOGELSTEIN, B
通讯作者：
VOGELSTEIN, B
影响因子：
45.3
作者：
SARKIS, AS;BAJORIN, DF;SCHER, HI
通讯作者：
SCHER, HI
影响因子：
6.6
作者：
Freiha, F;Reese, J;Torti, FM
通讯作者：
Torti, FM
DOI：
10.1111/j.1349-7006.1998.tb00551.x
发表时间：
1998-02-01
期刊：
JAPANESE JOURNAL OF CANCER RESEARCH
影响因子：
--
作者：
Kakehi, Y;Özdemir, E;Yoshida, O
通讯作者：
Yoshida, O